Quick Answer
Protalix BioTherapeutics, Inc. reported Operating Income Loss of -$5.50 million for the year ending 2025.
- Protalix BioTherapeutics, Inc. showed a decrease of -240.4% in Operating Income Loss from 2024 to 2025.
- This data is from Protalix BioTherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: -$8.77 million | Q1 2012: -$6.07 million | Q2 2012: $9.62 million | Q3 2012: -$5.56 million | Q1 2013: -$4.43 million | Q2 2013: -$6.89 million | Q3 2013: -$5.65 million | Q1 2014: -$6.47 million | Q2 2014: -$5.45 million | Q3 2014: -$6.21 million | Q1 2015: -$5.38 million | Q2 2015: -$5.58 million | Q3 2015: -$5.00 million | Q1 2016: -$7.86 million | Q2 2016: -$9.93 million | Q3 2016: -$6.65 million | Q1 2017: -$6.37 million | Q2 2017: -$10.81 million | Q3 2017: -$7.77 million | Q1 2018: -$5.15 million | Q2 2018: -$6.74 million | Q3 2018: -$3.74 million | Q4 2018: -$3.67 million | Q1 2019: -$5.53 million | Q2 2019: -$5.84 million | Q3 2019: -$1.54 million | Q4 2019: $2.20 million | Q1 2020: $4.69 million | Q2 2020: -$2.24 million | Q3 2020: -$2.58 million | Q1 2021: -$3.71 million | Q2 2021: -$9.17 million | Q3 2021: -$1.89 million | Q1 2022: -$1.87 million | Q2 2022: -$5.52 million | Q3 2022: -$3.13 million | Q1 2023: -$2.46 million | Q2 2023: $20.42 million | Q3 2023: -$1.89 million | Q1 2024: -$4.86 million | Q2 2024: -$2.43 million | Q3 2024: $3.99 million | Q1 2025: -$4.15 million | Q2 2025: $1.17 million | Q3 2025: $2.13 million.
- Over the full 17 years of available data (2009 to 2025), Protalix BioTherapeutics, Inc.'s Operating Income Loss has grown by 82.8%.
- Historical annual values: Fiscal year 2025: -$5.50 million | Fiscal year 2024: $3.92 million | Fiscal year 2023: $10.46 million | Fiscal year 2022: -$13.01 million | Fiscal year 2021: -$20.46 million | Fiscal year 2020: $2.71 million | Fiscal year 2019: -$10.72 million | Fiscal year 2018: -$19.31 million | Fiscal year 2017: -$34.52 million | Fiscal year 2016: -$33.16 million | Fiscal year 2015: -$23.67 million | Fiscal year 2014: -$28.56 million | Fiscal year 2013: -$34.06 million | Fiscal year 2012: -$12.17 million | Fiscal year 2011: -$36.53 million | Fiscal year 2010: -$29.97 million | Fiscal year 2009: -$31.97 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: